Effect of tofogliflozin on obesity-related health problems in patients with type 2 diabetes and overweight or obesity-a post-hoc sub-analysis of the UTOPIA study.

ABSTRACT:

Objective

This study aimed to evaluate the effects of tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, on health issues in patients with type 2 diabetes (T2DM) and overweight or obesity in real-world clinical practice.

Methods

This post-hoc sub-analysis of the UTOPIA trial, a randomized prospective study, included 210 patients (102 in the tofogliflozin group and 108 in the conventional treatment group) with a body mass index of ≥ 25.0 kg/m². The primary outcome was the percentage of patients achieving a weight loss of ≥ 3% at 26 and 104 weeks. Secondary outcomes included improvements in obesity-related health problems.

Results

At 26 weeks, 46.4% of the tofogliflozin group (95% confidence interval [CI] 36.2-56.8%) achieved a weight loss of 3% of mo

SUBMITTER: Katakami N 

PROVIDER: S-EPMC12532506 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature